Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Dermatology Practical & Conceptual|December 9, 2024
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective StudyLuigi Gargiulo, Luciano Ibba, Alessandra Narcisi, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2022
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis)Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, et al.Muscle & Nerve|June 28, 2024
Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort studyPietro E Doneddu, Riccardo Borroni, Angela Ceribelli, et al.Journal of Clinical Medicine|November 9, 2024
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective ExperienceMario Valenti, Andrea D'Arino, Enrico Melis, et al.The Journal of Dermatological Treatment|January 27, 2025
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.Dermatology and Therapy|May 15, 2024
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.International Journal of Dermatology|April 12, 2024
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patientsGianluca Nazzaro, Andrea Carugno, Paolo Bortoluzzi, et al.Journal of Clinical Medicine|January 23, 2024
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS)Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.Dermatology and Therapy|June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective StudyLuciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.Dermatology and Therapy|March 17, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis)Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.Pageof 8